Transmissible Spongiform Ecephalopathies (CQ3353)

Venue: Corinthia Towers Hotel

Location: Prague, Czech Republic

Event Date/Time: Jun 25, 2008 End Date/Time: Jun 26, 2008
Early Registration Date: May 23, 2008
Report as Spam


Informa’s 3rd annual conference on Transmittable Spongiform Encephalopathies will provide you with up-to date information on the latest advances in prion research. Specifically tailored to address the needs and challenges of the biopharmaceutical industry, this conference will help you review the latest discoveries and developments in TSE with special emphasis on the safety and risk to biological products. You will identify TSE risks in vaccine and antibody manufacture, address challenges in TSE removal and find out possible solutions.

This conference will ensure that you are informed about all risks and safety issues concerning your products and you will benefit from understanding the latest advances in TSE research and identifying the latest best practice approaches to the selection of spike material and methods for TSE cleaning studies for biopharmaceutical instruments.

Key topics include
TSE risk assessment for biopharmaceutical products
An update on pathology of TSE diseases
Regulatory Perspectives on TSE Safety
Progress and Detection and Quantitation of Infectivity
Industry Best Practice TSE contamination and removal methods

Don't Miss
Post-Conference Workshop: Thursday 27 June 2008
Viral and TSE Safety requirements for products from Phase I through to marketed product

This Conference is back-to-back with Viral Safety (23-24 June 2008)

Book on both events and save up to £400.


50% Discount for Academics and Start-up Biotech Companies- please contact Simon Lau for more details. +44 (0)20 7017 7165

Key PresentationsConfirmed speakers include:

Dr Gianluigi Zanusso, Department of Neurological and Visual Sciences, University of Verona, Italy
Dr Ruth Gabizon, Department of Neurology, Hadassah University Hospital, Israel
Dr Albrecht Gröner, Preclinical R&D / Virology, CSL Behring, Germany
Dr Albert Stühler, Deputy Head of Virus Safety Section, Paul-Ehrlich-Institut, Germany
Professor Claudio Soto, Department of Neurology, Neurosciences & Cell Biology, University of Texas Medical Branch, USA
Professor Giuseppe Legname, Neurobiology Sector, SISSA, Italy
Dr Alex J. Räber, Head of R&D, Prionics AG, Switzerland
Dr Ralph Zahn, Chief Executive Officer, Alicon AG, Switzerland
Dr Lisa A. Estey, Immunoassay R&D, IDEXX Laboratories, USA
Dr Gerald S. Baron, Investigator (TT), Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, NIAID, NIH, USA
Dr Markus Glatzel, Institute of Neuropathology, University Hospital Hamburg-Eppendorf, Germany
Dr Joëlle Chabry, Institut de Pharmacologie Moléculaire et Cellulaire, France Dr Pascal Leblanc, Human Virology Department, INSERM, France
Dr Didier Vilette, Dept, INRA, France
Dr Eckhard Flechsig, Institute of Virology and Immunobiology, University of Würzburg, Germany
Professor Maurizio Pocchiari, Department of Cell Biology & Neurosciences, Istituto Superiore di Sanita, Italy
Professor Sylvain Lehmann, Neurological Disorders and Stem Cells, Institute of Human Genetics, CNRS, France
Dr Anna Falbo, Head of Process and Analytical Development, Kedrion S.p.A., Italy
Joanne Dickinson, Project Team Leader –TSE Research Group, Health Protection Agency, Centre for Emergency Preparedness and Response, UK

This 2-day case-driven event will enable you to:

Review TSE risk assessment for biopharmaceutical products

Get updated on regulatory guidelines by experts who were involved in their composition.

Listen to in-depth case studies on TSE removal and decontamination
Hear about the latest developments on ante mortem diagnosis and discuss challenges in an interactive expert panel
Listen to the latest developments in TSE pathology and hear about the latest academic discoveries which may have an impact on the future of biopharmaceutical TSE testing.